Former Nivalis, MiRagen CMO hired by Netherlands-based biotech

BOULDER —  A biotech in the Netherlands on Monday said it has hired Dr. David Rodman, former chief medical officer at Boulder-based firms Nivalis Therapeutics Inc. and MiRagen Therapeutics Inc., as its chief development strategy officer.

In January, Nivalis (Nasdaq: NVLS), a developer of drugs to treat cystic fibrosis, cut Rodman and president and chief executive, Jon Congleton, as part of a restructuring plan to reduce expenses.

ProQR Therapeutics N.V. (Nasdaq: PRQR), which has an office in Palo Alto, Calif., also is developing drugs to treat cystic fibrosis.

SPONSORED CONTENT

Select your Republic Services residential cart now!

In preparation for Republic Services becoming the primary provider of residential recycling, yard trimmings, and trash, residents should now select the best cart size and service schedule for their household needs.

Rodman’s experience includes a leadership role in developing two approved medicines for cystic fibrosis at Vertex Pharmaceuticals. He was also the head of translational medicine at Novartis Institute for Biomedical Research. More recently, he was the chief medical officer at Nivalis and prior to Nivalis, he was chief medical officer at Boulder-based Miragen Therapeutics (Nasdaq: MGEN), which is focused on the discovery and development of microRNA-targeted therapies.

“At ProQR we are just beginning to capitalize on the power of RNA-based therapeutics,” Dr. Noreen R. Henig, ProQR’s chief medical officer, said in a prepared statement. “By adding Dave to our leadership, we will be able to strengthen our portfolio and strategically build our pipeline of RNA approaches to treating disease.”